StockNews.AI
AFMD
StockNews.AI
4 days

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

1. Affimed's AFM24 abstract accepted for AACR presentation in April 2025. 2. The abstract focuses on dose optimization for advanced non-small cell lung cancer. 3. AFM24 utilizes innate immune activation to target tumors effectively. 4. AACR acceptance may enhance investor confidence and stock visibility. 5. Full abstract releases online April 25, 2025, prior to the conference.

5 mins saved
Full Article

FAQ

Why Bullish?

The AACR presentation could generate positive investor interest, akin to past successful presentations by biotech firms. Companies like Moderna have seen stock price boosts following conference participations, reflecting similar investor sentiments around breakthrough therapies.

How important is it?

The AACR presentation is crucial as it may attract key stakeholders and boost clinical visibility.

Why Short Term?

Investor sentiments will likely shift around the AACR event, leading to immediate pricing impacts. Past examples show biotech stocks often react quickly to presentation outcomes.

Related Companies

MRNANKTXZMTP
March 25, 2025 16:30 ET  | Source: Affimed N.V. MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois. Details of the poster presentation are as follows: Title: Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Authors: Anthony El-Khoueiry, Omar Saavedra, Juanita Lopez, Hye Ryun Kim, Daniela Morales-Espinosa, Daniel Schütz, Andre Overesch, Andreas Harstrick, Kerstin Pietzko Session Category and Title: Phase II Clinical Trials 1 Session Date and Time: Tuesday, April 29, 2025, 9:00 AM – 12:00 PM CDT Location: Poster Section 49 Poster Board Number: 1 Published Abstract Number: CT161 The full abstract will be published online on April 25, 2025. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR. About AFM24AFM24 is a tetravalent, bispecific ICE® that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR), a protein widely expressed on solid tumors, to kill cancer cells. Generated by Affimed’s fit-for-purpose ROCK® platform, AFM24 represents a distinctive mechanism of action that uses EGFR as a docking site to engage innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells.  A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com. Investor Relations Contact Alexander FudukidisDirector, Investor RelationsE-Mail: a.fudukidis@affimed.comTel.: +1 (917) 436-8102 Media Contact Mary Beth Sandin Vice President, Marketing and CommunicationsE-Mail: m.sandin@affimed.com

Related News